Background: Presently, there are limited reports in the literature on
the post-operative (mid-term) clinical outcome for pure Aortic
Regurgitation (AR) following Transcatheter Aortic Valve Replacement
(TAVR). Methods: Between March 2014 and June 2019, a total of 134
high-risk patients with pure, symptomatic severe AR patients were
enrolled in the current study. The outcome was assessed according to the
VARC-2 criteria. Procedural results, clinical outcomes, and the
patients’ hemodynamics for a period of 1-year were analyzed. Results:
Patient mean was 73.1±6.4 years and 25.4% were female. The average STS
score was 9.8+5.3%. Procedural success was 97.1% (130/134), and the
device success rate was 96.3% (129/134). Five cases were converted to
open surgery, while two patients underwent valvular reinterventions
(surgical aortic valve replacement for thrombosis and increasing
paravalvular regurgitation). The mean aortic valve gradient was 10.2±4.1
mmHg, while the moderate and severe aortic regurgitation was 1.6% at 1
year. Paravalvular regurgitation was none/trivial in 79.8% and mild in
18.5%. The 1-year all-cause mortality rate was 7.4%. At 1-year, the
stroke incidence rate was 2.2%. And pacemaker was implanted in 8.9% of
the enrolled patients. Conclusions: In high-risk patients undergoing
transapical-TAVR for AR, the use of the J-Valve is safe and effective
TAVR should be considered as a reasonable option for high-risk patients
with pure AR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.